Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JZQ-B4 CAR T cells
- Development stage
- Preclinical
- Lead developer
- Weill Cornell Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JZQ-B4 CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target Mesothelin (MSLN), a cell-surface glycoprotein overexpressed in several solid malignancies, including mesothelioma, lung, and ovarian cancers. The CAR construct utilizes a high-affinity single-domain antibody (VHH or nanobody) binder, JZQ-B4, which was derived from immunized alpacas and demonstrates cross-reactivity with both human and mouse MSLN. This cross-species reactivity allows for the evaluation of on-target, off-tumor toxicities in preclinical mouse models. While the parental JZQ-B4 CAR T cells exhibit potent antitumor activity, research has shown that their high affinity can lead to lethal systemic toxicity by targeting normal tissues with low MSLN expression. Consequently, JZQ-B4 serves as a scaffold for affinity-tuning strategies to improve the safety profile of MSLN-targeted cellular therapies.
- Other names
- Anti-MSLN VHH CAR T cellsMesothelin-targeting VHH CAR T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on JZQ-B4 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JZQ-B4 CAR T cells.